von Tobias Borgers | Nov. 12, 2019 | Bayer
Bayer’s new corporate campaign—the largest in its history—turns science into a verb. The effort, “Why We Science,” launched recently with a series of TV ads along with digital and social media to show the value of Bayer products, from healthcare to agriculture, in...
von Tobias Borgers | Nov. 6, 2019 | Bayer
The Global Contrast Media (Contrast Agents) Market analysis is meticulous study which provides a holistic view of the global Contrast Media (Contrast Agents) market featuring different innovative trends of the global market along with the impact of trends on global...
von Tobias Borgers | Okt. 27, 2019 | Bayer
Some credit Bayer AG (XTER: BAYN) with making the worst corporate deal in recent memory. With a market cap of about $62 billion, the German conglomerate’s value is below what it paid for Monsanto last year. Even Houdini would have a difficult time making the...
von Tobias Borgers | Okt. 20, 2019 | Bayer
Bayer will invest more than $30 million over the next five years to fund collaborative research projects focused on finding new treatments for chronic lung diseases, including chronic obstructive pulmonary disease (COPD). The projects will be developed in a new lab...
von Tobias Borgers | Okt. 10, 2019 | Bayer
Berlin, 10. Oktober 2019 – Bayer gab heute die Kooperation mit elf Startup-Firmen im digitalen Gesundheitsbereich bekannt. Der Pharmakonzern strebt im Rahmen des Programms langfristige Partnerschaften an, um spezifische, digitale Lösungen für eine verbesserte...
von Tobias Borgers | Okt. 9, 2019 | Bayer
Bayer and RIKEN partner for novel drug discovery The Pharma Letter Link zum Originalbeitrag
